CALL/EVOTEC/20/0.1/20.09.24 Share Price

Warrant

DE000GQ54H28

Real-time BOERSE MUENCHEN 13:26:57 26/06/2024 BST
0.008 EUR -11.11% Intraday chart for CALL/EVOTEC/20/0.1/20.09.24
Current month-25.00%
1 month-52.63%
Date Price Change
26/06/24 0.008 -11.11%
25/06/24 0.009 -10.00%
24/06/24 0.01 -23.08%
21/06/24 0.013 0.00%
20/06/24 0.013 0.00%

Real-time BOERSE MUENCHEN

Last update June 26, 2024 at 01:26 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying EVOTEC SE
Issuer Goldman Sachs
WKN GQ54H2
ISINDE000GQ54H28
Date issued 19/09/2023
Strike 20
Maturity 20/09/2024 (86 Days)
Parity 10 : 1
Emission price 0.41
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.45
Lowest since issue 0.008
Spread 0.01
Spread %55.56%

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.825 EUR
Average target price
20.79 EUR
Spread / Average Target
+135.58%
Consensus